fda compounding semaglutide crackdown 2025 news The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday How GLP-1 weight loss compounders

In the SUSTAIN trial, 52% of patients receiving semaglutide experienc ed gastrointestinal side effects, compared with 35% in the placebo group

The compound was developed by the Australian biotech firm Metabolic Pharmaceuticals as a research tool to isolate the lipolytic signaling domain of growth hormone without the receptor-binding region responsible for its anabolic and glucose-handling effects

doi: 10.1124/jpet.119.258343

Impact on Type 2 Diabetes For participants with type 2 diabetes, retatrutide significantly improved glycemic parameters

Weight loss was also assessed in the SCALE Sleep Apnea RCT, in which 359 non-diabetic individuals (mean age 48.5 years, mean BMI 39.1 kg/m 2 ), mostly males with untreated obstructive sleep apnea (OSA), were enrolled to investigate the effect of liraglutide on disease severity 20

Users typically experience reduced hunger and better portion control